Float Short %

6.75

Margin Of Safety %

Put/Call OI Ratio

0.98

EPS Next Q Diff

0.32

EPS Last/This Y

EPS This/Next Y

2.69

Price

92.25

Target Price

126.79

Analyst Recom

1.71

Performance Q

2.3

Relative Volume

0.92

Beta

0.55

Ticker: BPMC

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-01-23	BPMC	115.78	0.89	2.04	30392
2025-01-24	BPMC	114.98	1.10	0.44	36767
2025-01-27	BPMC	113.97	1.07	0.07	37407
2025-01-28	BPMC	114.5	1.07	0.06	37404
2025-01-29	BPMC	114.44	1.06	0.13	37522
2025-01-30	BPMC	114.04	1.02	1.65	38620
2025-01-31	BPMC	112.46	1.03	0.37	39254
2025-02-03	BPMC	111.5	1.01	0.06	40099
2025-02-04	BPMC	113.42	0.99	0.76	40681
2025-02-05	BPMC	110.44	0.98	0.05	40734
2025-02-06	BPMC	109.58	0.98	0.27	40905
2025-02-07	BPMC	104.99	0.97	0.01	41255
2025-02-10	BPMC	103.93	0.93	0.02	42180
2025-02-11	BPMC	101.57	0.88	0.46	43313
2025-02-12	BPMC	103.6	0.88	0.15	43490
2025-02-13	BPMC	95.26	0.87	1.15	44068
2025-02-14	BPMC	94	0.89	0.10	45149
2025-02-18	BPMC	92.43	0.89	0.03	45138
2025-02-19	BPMC	94.15	0.99	0.33	42852
2025-02-20	BPMC	94.36	0.99	0.03	43023
2025-02-21	BPMC	92.28	0.98	1.17	43211
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-01-23	BPMC	115.63	63.4	104.5	-1.40
2025-01-24	BPMC	114.96	63.4	103.8	-1.40
2025-01-27	BPMC	113.99	63.4	103.8	-1.40
2025-01-28	BPMC	114.47	63.4	104.0	-1.40
2025-01-29	BPMC	114.35	63.4	103.9	-1.40
2025-01-30	BPMC	114.05	61.8	103.9	-1.40
2025-01-31	BPMC	112.38	61.8	103.7	-1.40
2025-02-03	BPMC	111.50	61.8	103.8	-1.40
2025-02-04	BPMC	113.38	61.8	104.2	-1.40
2025-02-05	BPMC	110.34	61.8	103.5	-1.40
2025-02-06	BPMC	109.67	61.8	103.8	-1.40
2025-02-07	BPMC	104.97	61.8	103.3	-1.40
2025-02-10	BPMC	104.00	61.8	103.8	-1.40
2025-02-11	BPMC	101.48	61.8	103.5	-1.40
2025-02-12	BPMC	103.65	61.8	104.2	-1.40
2025-02-13	BPMC	95.26	61.8	102.7	-1.40
2025-02-14	BPMC	93.94	61.8	103.7	-0.81
2025-02-18	BPMC	92.43	74.4	11.3	-1.28
2025-02-19	BPMC	94.07	74.4	-54.4	-1.28
2025-02-20	BPMC	94.31	74.4	-53.6	-1.28
2025-02-21	BPMC	92.25	74.4	-52.3	-1.28
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-01-23	BPMC	-9.07	-1.46	8.19
2025-01-24	BPMC	-10.29	-1.46	8.19
2025-01-27	BPMC	-10.29	-1.51	8.19
2025-01-28	BPMC	-10.39	-1.51	8.26
2025-01-29	BPMC	-10.39	-1.51	8.26
2025-01-30	BPMC	-10.39	-1.51	8.26
2025-01-31	BPMC	-10.39	-1.51	8.26
2025-02-03	BPMC	-10.39	-1.02	8.26
2025-02-04	BPMC	-10.39	-1.02	8.26
2025-02-05	BPMC	-10.39	-1.02	8.26
2025-02-06	BPMC	-10.39	-1.02	8.26
2025-02-07	BPMC	-10.39	-1.02	8.26
2025-02-10	BPMC	-7.60	-0.38	8.29
2025-02-11	BPMC	-6.45	-0.38	8.29
2025-02-12	BPMC	-6.45	-0.38	6.79
2025-02-13	BPMC	-6.45	-0.38	6.79
2025-02-14	BPMC	-7.53	-0.38	6.77
2025-02-18	BPMC	-7.49	-1.28	6.73
2025-02-19	BPMC	-6.31	-1.28	6.75
2025-02-20	BPMC	-6.05	-1.28	6.75
2025-02-21	BPMC	-6.08	-1.28	6.75
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.79

Avg. EPS Est. Current Quarter

-0.34

Avg. EPS Est. Next Quarter

-0.47

Insider Transactions

-6.08

Institutional Transactions

-1.28

Beta

0.55

Average Sales Estimate Current Quarter

160

Average Sales Estimate Next Quarter

176

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

26.6

Max Drawdown 5-Year %

-69.5

Target Price

126.79

P/E

Forward P/E

77.49

PEG

P/S

11.59

P/B

19.68

P/Free Cash Flow

EPS

-1.07

Average EPS Est. Cur. Y

-1.28

EPS Next Y. (Est.)

1.41

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-13.19

Relative Volume

0.92

Return on Equity vs Sector %

-41.7

Return on Equity vs Industry %

-26.1

EPS 1 7Days Diff

-0.3

EPS 1 30Days Diff

-0.35

EBIT Estimation

-52.3

Blueprint Medicines Corporation

Sector: Healthcare

Industry: Biotechnology

Employees: 649

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

stock quote shares BPMC – Blueprint Medicines Corporation Stock Price stock today

news today BPMC – Blueprint Medicines Corporation stock forecast ,stock prediction 2023 2024 2025

marketwatch BPMC – Blueprint Medicines Corporation yahoo finance google finance

stock history BPMC – Blueprint Medicines Corporation invest stock market

stock prices BPMC premarket after hours

ticker BPMC fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: BPMC

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y